Hypoglycemia risk is generally low when used as monotherapy but increases when combined with insulin or sulfonylureas
Novo Nordisk Inc., FDA approves Novo Nordisks Wegovy pill, the first and only oral GLP-1 for weight loss in adults (2025).
There are currently no published clinical trials evaluating the safety or efficacy of compounded GLP-1 ODTs
This is not a character failure
Commercially available GLP-1 support patches are typically applied for 8 hours
Menopause, sleep disruption, vasomotor symptoms, insulin resistance, body-composition changes, thyroid dysfunction, low testosterone, and chronic stress signaling can all influence how patients feel, recover, move, sleep, and maintain metabolic health